Atox Bio Revenue and Competitors
Estimated Revenue & Valuation
- Atox Bio's estimated annual revenue is currently $1.6M per year.
- Atox Bio's estimated revenue per employee is $77,500
- Atox Bio's total funding is $58.4M.
Employee Data
- Atox Bio has 21 Employees.
- Atox Bio grew their employee count by 91% last year.
Atox Bio's People
| Name | Title | Email/Phone |
|---|
Atox Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11.2M | 63 | 7% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | N/A | 15 | 7% | N/A | N/A |
#6 | $0.9M | 11 | -39% | N/A | N/A |
#7 | $1.7M | 9 | 0% | N/A | N/A |
#8 | $0.6M | 3 | 0% | N/A | N/A |
#9 | $4.8M | 31 | -6% | N/A | N/A |
#10 | $6.4M | 36 | 6% | N/A | N/A |
What Is Atox Bio?
Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Reltecimod (AB103) , the company?s lead product, is studied in ACCUTE (Reltecimod Clinical Composite endpoint Study in necrotizing soft Tissue InfEctions), a phase 3 clinical trial in patients with Necrotizing Soft Tissue Infections, a rare, life threatening infection for which no therapy currently exists. Reltecimod is also being studied in REAKT (Reltecimod Efficacy for Acute Kidney Injury Trial), a phase 2 study in patients with abdominal sepsis induced Acute Kidney Injury. Reltecimod received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
keywords:N/A
$58.4M
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
91%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Atox Bio News
Atox Bio Ltd; Bristol-myers Squibb Co; Five Prime Therapeutics Inc; Johnson & Johnson; Theramab Llc T Cell Specific Surface Glycoprotein Cd28...
The key players operating in the Acute Kidney Injury treatment market include Atox Bio, AM-Pharma, Angion Biomedica, Astellas Pharma,...
Atox Bio, a Ness Ziona, Israel and Chapel Hill, NC –based clinical stage biotechnology company developing novel therapies for critically ill patients, raised $30m in funding. The round was led by Arix Bioscience plc with participation from Adams Street Partners, Asahi Kasei Corporation and addi ...
Israel’s Atox Bio has raised $30 million — the latest in a long line of equity deals — to help push its immune modulators through late-stage clinical trials. The company is working on immune modulators for patients with severe infections and tissue injury. The company ...
Atox Bio, a Ness Ziona, Israel-based developer of therapeutics for severe infections, raised up to $23m in Series E investment. The round was led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel. The company intends to use the funds to initiate a late stage clinical stu ...
Other Companies in Chapel Hill
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.5M | 21 | -12% | N/A |
#2 | $2.1M | 21 | N/A | N/A |
#3 | $4.3M | 21 | -12% | N/A |
#4 | $1.6M | 21 | 24% | N/A |
#5 | $2M | 21 | 11% | N/A |